Follow-On Biologics One Possible Fruit Of FDA-Northeastern Collaboration
Executive Summary
A research collaboration agreement between FDA and Northeastern University could help agency officials understand the mechanisms of action of follow-on biologics, thus easing the way for these products once Congress establishes an approval pathway
You may also be interested in...
FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements
FDA's Decision-Making Process For ANDA Approval Standards Questioned In Vancomycin Case; Would Process Changes Alter The Outcome?
ViroPharma has fired another shot across FDA's bow in the continuing battle over approval standards for generic oral vancomycin, charging in a petition supplement that the Office of Generic Drugs' decision to change bioequivalence methods for this antibiotic "was fraught with irregularities.
FDA Immunogenicity Testing Guidance Is High-Wire Act For Brand Industry
The biotech industry faces a tightrope challenge in commenting on FDA's draft guidance on assay development for immunogenicity testing of therapeutic proteins. Companies want clarity from the agency, as well as limits to the scope of the guidelines. But firms also want to make sure that however the lines are drawn, follow-on biologics have strict testing requirements